The Buczynski–Gregus Laboratory investigates how bioactive lipids, neuropeptides, and their receptors shape behavior in alcohol use disorder, chronic pain, and Parkinson’s disease. We integrate behavioral neuroscience, molecular pharmacology, and mass spectrometry to discover disease-associated signaling pathways, establish their functional roles, and evaluate new therapeutic strategies.
Questions of interest to the lab include:
1) Which molecular and cellular signaling pathways contribute to the development of disease symptoms and pathology?
2) Can existing drugs be repurposed to to improve symptoms or slow disease progression?
3) Can novel therapeutic targets be identified that could improve symptoms or slow disease progression?
4) Can molecular biomarkers identify patient subpopulations, track disease progression, or predict treatment response?
5) How do biological sex and environmental factors influence disease mechanisms, symptom presentation, and treatment outcomes?
Alcohol Use Disorder
Chronic Pain
Parkinson's Disease
